糖尿病性腎臓病の世界市場レポート 2025年

糖尿病性腎臓病の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.1％で35億6,000万米ドルに成長します。予測期間の成長は、個別化医療とバイオマーカー開発、世界の糖尿病罹患率の上昇、疾患修飾療法への注力、テレヘルスと遠隔ケア、ヘルスケア政策と償還の変化などに起因すると考えられます。予測期間における主な動向は、腎代替療法の進歩、精密医療アプローチ、早期発見・診断への注力、治療の進歩、併存疾患管理の増加などです。

慢性腎臓病の有病率の上昇が糖尿病性腎臓病市場の成長を牽引すると予測されます。慢性腎臓病（CKD）は、腎臓の機能が徐々に低下し、高血圧、貧血、骨疾患などのさまざまな合併症を引き起こす長期的な疾患です。慢性腎臓病の治療には診断と治療が必要であり、これが最終的に糖尿病性腎臓病市場の拡大を後押ししています。例えば、2023年6月、英国の著名な慈善団体であるKidney Research UKは、慢性腎臓病は英国で約720万人が罹患しており、人口の10％以上に相当すると報告しています。このうち、325万人が最も重症の段階にあり、約390万人が未治療で無症状のことが多い初期の段階にあります。予測によると、英国における慢性腎臓病患者総数は2033年までに761万人に増加する可能性があります。このように、慢性腎臓病の有病率の増加が糖尿病性腎臓病市場の成長を促進しています。

ヘルスケア支出の増加は、今後の糖尿病性腎臓病市場の成長を促進すると予想されます。ヘルスケア支出とは、特定の期間内にヘルスケア関連の商品やサービスに割り当てられる総資金のことで、通常は国や機関レベルで行われます。ヘルスケア支出の増加は高度な診断技術の採用を促進し、糖尿病性腎臓病の早期かつ正確な発見を可能にし、タイムリーな介入と治療を促進します。例えば、2023年5月、英国の政府部門である国家統計局は、英国のヘルスケア支出は2022～2023年にかけて5.6％増加したと報告し、英国のヘルスケア支出は、2023年には約2,920億英ポンドとなりました。したがって、ヘルスケア支出の増加が糖尿病性腎臓病市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の糖尿病性腎臓病市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の糖尿病性腎臓病市場：成長率分析
• 世界の糖尿病性腎臓病市場の実績：規模と成長、2019～2024年
• 世界の糖尿病性腎臓病市場の予測：規模と成長、2024～2029年、2034年
• 世界の糖尿病性腎臓病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病性腎臓病市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 1型糖尿病
• 2型糖尿病
• 世界の糖尿病性腎臓病市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• アンジオテンシン受容体拮抗薬（ARB）
• アンジオテンシン変換酵素（ACE）阻害剤
• 抗酸化炎症調節剤
• カルシウム拮抗薬
• その他
• 世界の糖尿病性腎臓病市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ホームケア
• 専門センター
• その他
• 世界の糖尿病性腎臓病市場：1型糖尿病のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 自己免疫関連糖尿病性腎臓病
• 早期発症糖尿病性腎臓病
• 世界の糖尿病性腎臓病市場：2型糖尿病のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肥満関連糖尿病性腎臓病
• 遅発性糖尿病性腎臓病

第7章 地域別・国別分析

• 世界の糖尿病性腎臓病市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の糖尿病性腎臓病市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病性腎臓病市場：競合情勢
• 糖尿病性腎臓病市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Fresenius SE & Co. KGaA
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Reata Pharmaceuticals Inc.
• Merck & Co.
• Mitsubishi Tanabe Pharma Corporation
• Johnson & Johnson pvt. Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• AbbVie Inc.
• Boehringer Ingelheim International GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖尿病性腎臓病市場2029年：新たな機会を提供する国
• 糖尿病性腎臓病市場2029年：新たな機会を提供するセグメント
• 糖尿病性腎臓病市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Diabetic kidney disease is a form of renal disease resulting from complications of diabetes, where elevated blood sugar levels lead to kidney damage. The kidneys' blood vessels can be adversely affected by high blood glucose, reducing their functionality.

The primary types of diabetic kidney disease are associated with both type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition characterized by minimal or no insulin production by the pancreas. This deficiency leads to elevated blood sugar levels, causing damage to the nephrons and renal blood vessels. Managing blood sugar levels in type 1 diabetes often requires daily insulin injections. Treatment for diabetic kidney disease includes interventions such as angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other medical approaches provided in facilities such as hospitals, homecare, specialty centers, and more.

The diabetic kidney disease market research report is one of a series of new reports from The Business Research Company that provides diabetic kidney disease market statistics, including global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic kidney disease market size has grown strongly in recent years. It will grow from $2.67 billion in 2024 to $2.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to early understanding of diabetes complications, advancements in diagnostic techniques, development of ace inhibitors and arbs, clinical trials and treatment protocols, guidelines and disease management protocols.

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.56 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to personalized medicine and biomarker development, rising global diabetes incidence, focus on disease modification therapies, telehealth and remote care, healthcare policy and reimbursement changes. Major trends in the forecast period include advancements in renal replacement therapies, precision medicine approach, focus on early detection and diagnosis, therapeutic advancements, rise in comorbidities management.

The rising prevalence of chronic kidney disease is anticipated to drive the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) is a long-term condition that leads to a gradual loss of kidney function, resulting in various complications such as high blood pressure, anemia, and bone diseases. Treating chronic kidney diseases necessitates diagnostic and treatment options, which ultimately fuels the expansion of the diabetic kidney disease market. For instance, in June 2023, Kidney Research UK, a prominent charity in the UK, reported that chronic kidney disease affects approximately 7.2 million people in the United Kingdom, representing over 10% of the population. Among these individuals, 3.25 million are in the most severe stages of the disease, while around 3.9 million are in the early stages, which are often untreated and asymptomatic. Projections suggest that the total number of individuals with chronic kidney disease in the United Kingdom could rise to 7.61 million by 2033. Thus, the increasing prevalence of chronic kidney disease is propelling the growth of the diabetic kidney disease market.

The growing healthcare expenditure is expected to enhance the growth of the diabetic kidney disease market in the future. Healthcare expenditure refers to the total funds allocated for healthcare-related goods and services within a specific timeframe, typically at a national or institutional level. Increased healthcare spending promotes the adoption of advanced diagnostic technologies, enabling early and accurate detection of diabetic kidney disease and facilitating timely intervention and treatment. For example, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. The UK healthcare expenditure was approximately £292 billion in 2023. Therefore, the rising healthcare expenditure is driving the growth of the diabetic kidney disease market.

Technological advancements emerge as a pivotal trend gaining traction in the diabetic kidney disease market. Companies within this sector embrace novel technologies to fortify their market standing. For instance, in August 2022, Bloom Diagnostics, a US-based organization specializing in diagnostics and healthcare devices, introduced the Bloom Kidney Test. Integrated with the Bloom Smart System, this diagnostic tool evaluates kidney health by measuring cystatin C levels-a reliable indicator of kidney function. Categorizing kidney function into three stages-normal, mildly decreased, and decreased-the Bloom Kidney Test leverages cloud-based algorithms and AI technology within the Bloom Smart System. This integration combines test outcomes with pertinent health data such as medical history, lifestyle, and patient symptoms, facilitating comprehensive analysis and management.

Leading companies in the diabetic kidney disease market are actively innovating by developing new products such as medications tailored for chronic kidney disease (CKD), aiming for wider customer reach, increased sales, and revenue growth. These medications for CKD primarily focus on symptom management, slowing disease progression, and addressing complications arising from impaired kidney function. For instance, Bayer AG, a Germany-based pharmaceutical company, introduced Kerendia in August 2022-a medication specifically designed to manage CKD associated with diabetes. Kerendia stands out as a non-steroidal, selective mineralocorticoid receptor antagonist, uniquely tailored for individuals with chronic kidney disease linked to type-II diabetes. Offering a distinctive treatment approach, Kerendia holds promise in slowing CKD progression and reducing the risk of kidney failure in this susceptible patient group.

In January 2023, AstraZeneca, a UK-based biotech and pharmaceutical giant, finalized the acquisition of Cincor Pharma Inc. for an undisclosed sum. This strategic move strengthens AstraZeneca's cardiorenal pipeline by integrating CinCor's baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) aimed at lowering blood pressure in treatment-resistant hypertension. Cincor Pharma Inc., a US-based biopharmaceutical company, specializes in developing drugs for kidney disease management. AstraZeneca's acquisition bolsters its portfolio by incorporating innovative solutions such as baxdrostat, further solidifying its position in addressing cardiorenal complications and advancing therapeutic options for kidney disease management.

Major companies operating in the diabetic kidney disease market include AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited

North America was the largest region in the diabetic kidney disease market in 2024. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Kidney Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic kidney disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic kidney disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1 Diabetes; Type 2 Diabetes
• 2) By Treatment: Angiotensin Receptor Blockers (Arbs); Angiotensin-Converting Enzyme (Ace) Inhibitors; Antioxidant Inflammation Modulator; Calcium Channel Blockers; Other Treatments
• 3) By End User: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By Type 1 Diabetes: Autoimmune-Related Diabetic Kidney Disease; Early-Onset Diabetic Kidney Disease
• 2) By Type 2 Diabetes: Obesity-Related Diabetic Kidney Disease; Late-Onset Diabetic Kidney Disease
• Companies Mentioned: AstraZeneca plc; Pfizer Inc.; Novartis AG; Bayer AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Kidney Disease Market Characteristics

3. Diabetic Kidney Disease Market Trends And Strategies

4. Diabetic Kidney Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Kidney Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Kidney Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Kidney Disease Market Growth Rate Analysis
• 5.4. Global Diabetic Kidney Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Kidney Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Kidney Disease Total Addressable Market (TAM)

6. Diabetic Kidney Disease Market Segmentation

• 6.1. Global Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes
• Type 2 Diabetes
• 6.2. Global Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin Receptor Blockers (Arbs)
• Angiotensin-Converting Enzyme (Ace) Inhibitors
• Antioxidant Inflammation Modulator
• Calcium Channel Blockers
• Other Treatments
• 6.3. Global Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End Users
• 6.4. Global Diabetic Kidney Disease Market, Sub-Segmentation Of Type 1 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune-Related Diabetic Kidney Disease
• Early-Onset Diabetic Kidney Disease
• 6.5. Global Diabetic Kidney Disease Market, Sub-Segmentation Of Type 2 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obesity-Related Diabetic Kidney Disease
• Late-Onset Diabetic Kidney Disease

7. Diabetic Kidney Disease Market Regional And Country Analysis

• 7.1. Global Diabetic Kidney Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Kidney Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Kidney Disease Market

• 8.1. Asia-Pacific Diabetic Kidney Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Kidney Disease Market

• 9.1. China Diabetic Kidney Disease Market Overview
• 9.2. China Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Kidney Disease Market

• 10.1. India Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Kidney Disease Market

• 11.1. Japan Diabetic Kidney Disease Market Overview
• 11.2. Japan Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Kidney Disease Market

• 12.1. Australia Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Kidney Disease Market

• 13.1. Indonesia Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Kidney Disease Market

• 14.1. South Korea Diabetic Kidney Disease Market Overview
• 14.2. South Korea Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Kidney Disease Market

• 15.1. Western Europe Diabetic Kidney Disease Market Overview
• 15.2. Western Europe Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Kidney Disease Market

• 16.1. UK Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Kidney Disease Market

• 17.1. Germany Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Kidney Disease Market

• 18.1. France Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Kidney Disease Market

• 19.1. Italy Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Kidney Disease Market

• 20.1. Spain Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Kidney Disease Market

• 21.1. Eastern Europe Diabetic Kidney Disease Market Overview
• 21.2. Eastern Europe Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Kidney Disease Market

• 22.1. Russia Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Kidney Disease Market

• 23.1. North America Diabetic Kidney Disease Market Overview
• 23.2. North America Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Kidney Disease Market

• 24.1. USA Diabetic Kidney Disease Market Overview
• 24.2. USA Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Kidney Disease Market

• 25.1. Canada Diabetic Kidney Disease Market Overview
• 25.2. Canada Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Kidney Disease Market

• 26.1. South America Diabetic Kidney Disease Market Overview
• 26.2. South America Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Kidney Disease Market

• 27.1. Brazil Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Kidney Disease Market

• 28.1. Middle East Diabetic Kidney Disease Market Overview
• 28.2. Middle East Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Kidney Disease Market

• 29.1. Africa Diabetic Kidney Disease Market Overview
• 29.2. Africa Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Kidney Disease Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Kidney Disease Market Competitive Landscape
• 30.2. Diabetic Kidney Disease Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Kidney Disease Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Aurobindo Pharma Ltd.
• 31.5. Fresenius SE & Co. KGaA
• 31.6. F. Hoffmann-La Roche AG
• 31.7. Abbott Laboratories
• 31.8. Reata Pharmaceuticals Inc.
• 31.9. Merck & Co.
• 31.10. Mitsubishi Tanabe Pharma Corporation
• 31.11. Johnson & Johnson pvt. Ltd.
• 31.12. Eli Lilly and Company
• 31.13. GlaxoSmithKline plc
• 31.14. AbbVie Inc.
• 31.15. Boehringer Ingelheim International GmbH

32. Global Diabetic Kidney Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Kidney Disease Market

34. Recent Developments In The Diabetic Kidney Disease Market

35. Diabetic Kidney Disease Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Kidney Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Kidney Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Kidney Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer